DalsnaFinance

Xenon Pharmaceuticals Inc $XENE

Health Care

Russell 2000 Canada
Create a scorecard
$36.50
+0.55 (+1.53%)
As of Oct 22, 2026, 6:59 PM EDT
Price history
Loading chart…

Xenon Pharmaceuticals Inc (XENE) is trading up at $36.50 (+1.53%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

Xenon Pharmaceuticals Inc revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$32.2M−$156.9M−$345.9MFY2016 revenue: $1.80MFY2016 net income: −$23.0M · Net margin −1275.5%'16FY2017 revenue: $311.0KFY2017 net income: −$30.7M · Net margin −9872.7%'17FY2018 net income: −$34.5M'18FY2019 revenue: $6.83MFY2019 net income: −$41.6M · Net margin −609.1%'19FY2020 revenue: $32.2MFY2020 net income: −$28.8M · Net margin −89.7%'20FY2021 revenue: $18.4MFY2021 net income: −$78.9M · Net margin −427.8%'21FY2022 revenue: $9.43MFY2022 net income: −$125.4M · Net margin −1328.9%'22FY2023 revenue: $0FY2023 net income: −$182.4M'23FY2024 revenue: $0FY2024 net income: −$234.3M'24FY2025 revenue: $7.50MFY2025 net income: −$345.9M · Net margin −4612.1%'25−100%−75%−50%−25%0%FY2016 net margin: −1275.5% (off the scale, which stops at −100.0%)FY2017 net margin: −9872.7% (off the scale, which stops at −100.0%)FY2019 net margin: −609.1% (off the scale, which stops at −100.0%)FY2020 net margin: −89.7%FY2021 net margin: −427.8% (off the scale, which stops at −100.0%)FY2022 net margin: −1328.9% (off the scale, which stops at −100.0%)FY2025 net margin: −4612.1% (off the scale, which stops at −100.0%)
Xenon Pharmaceuticals Inc annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$1.80M$311.0K—$6.83M$32.2M$18.4M$9.43M$0$0$7.50M
Growth (year over year)−88.4%−82.8%——+371.0%−42.7%−48.8%−100.0%——
Operating income−$24.8M−$32.6M−$38.0M−$42.8M−$31.3M−$79.0M−$129.1M−$214.1M−$279.3M−$373.1M
Operating margin−1376.4%−10474.3%—−627.0%−97.3%−428.4%−1368.9%——−4974.3%
Net income−$23.0M−$30.7M−$34.5M−$41.6M−$28.8M−$78.9M−$125.4M−$182.4M−$234.3M−$345.9M
Net margin−1275.5%−9872.7%—−609.1%−89.7%−427.8%−1328.9%——−4612.1%
EPS (diluted)−$1.48−$1.72−$1.63−$1.54−$0.81−$1.77−$2.06−$2.73−$3.01−$4.36
Balance sheet
Cash and equivalents$17.1M$20.5M$67.8M$24.8M$45.0M$175.7M$57.2M$148.6M$142.7M$199.2M
Total assets$67.5M$46.1M$122.4M$147.7M$189.2M$572.0M$754.1M$964.8M$798.1M$633.2M
Total liabilities$3.59M$10.2M$19.1M$55.7M$17.8M$22.0M$32.6M$36.9M$43.2M$51.4M
Long-term debt—$6.10M$15.0M$10.9M——————
Shareholders' equity$63.9M$35.9M$103.3M$92.0M$171.4M$550.0M$721.5M$927.9M$754.9M$581.8M
Cash flow
Operating cash flow−$19.6M−$28.7M−$34.7M−$4.71M−$48.1M−$69.5M−$101.0M−$151.1M−$181.4M−$279.1M
Capital expenditure$279.0K$315.0K$507.0K$1.24M$2.64M$2.05M$2.89M$5.62M$3.08M$799.0K
Free cash flow−$19.8M−$29.0M−$35.2M−$5.95M−$50.8M−$71.6M−$103.9M−$156.7M−$184.5M−$279.9M

From Xenon Pharmaceuticals Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. Filings on SEC EDGAR →

About Xenon Pharmaceuticals Inc

Headquarters
Burnaby, Canada From SEC filings, Oct 2026

Recent News (4)

More Health Care stocks

Browse all companies →